Volume 29, Issue 1

Search all Breast Cancer articles

January 2022

21 articles in this issue

Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan
Daisuke Yotsumoto
Yasuaki Sagara
Hiromitsu Jinno
Special Article 19 October 2021 Pages: 1 - 8
Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?
J. Díaz-Roldán
M. Eguía-Larrea
L. Muñoz-Bellvís
Review Article 15 October 2021 Pages: 9 - 18
Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging
Suneela Vegunta
Asha A. Bhatt
Aparna S. Kaur
Review Article 19 October 2021 Pages: 19 - 29
Perceived physical fatigability improves after an exercise intervention among breast cancer survivors: a randomized clinical trial
Yujia Qiao
G. J. van Londen
Nancy W. Glynn
Original Article 30 July 2021 Pages: 30 - 37
Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer
Derrick G. Lee
Johanna M. Schuetz
John J. Spinelli
Original Article 05 August 2021 Pages: 38 - 49
Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of cN0 and cN + patients
Leili Zarifmahmoudi
Atena Aghaee
Ramin Sadeghi
Original Article 02 August 2021 Pages: 50 - 64
LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299
Shu-Lin Huang
Zhong-Cheng Huang
Pei-Zhi Fan
Original Article Open access 05 August 2021 Pages: 65 - 76
Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors
Yuna Suzuki
Wu Wenwen
Shin-ichi Hayashi
Original Article 03 August 2021 Pages: 77 - 91
Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study
Su-Jin Koh
Shozo Ohsumi
Judith Balmaña
Original Article Open access 31 August 2021 Pages: 92 - 102
High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer
Liang Zhu
Jia-Ni Pan
Wen-Ming Cao
Original Article Open access 17 August 2021 Pages: 103 - 113
Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy
A. T. P. M. Brands-Appeldoorn
A. J. G. Maaskant-Braat
R. M. H. Roumen
Original Article Open access 26 August 2021 Pages: 114 - 120
Integrated analysis of cell cycle-related genes in HR+/HER2− breast cancer
Jianguo Lai
Bo Chen
Ning Liao
Original Article 27 August 2021 Pages: 121 - 130
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
Naruto Taira
Kosuke Kashiwabara
Fumikata Hara
Original Article 07 September 2021 Pages: 131 - 143
FE65 in breast cancer and its clinicopathological significance
Junyao Xu
Erina Iwabuchi
Hironobu Sasano
Original Article 08 September 2021 Pages: 144 - 155
Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Eriko Tokunaga
Takanobu Masuda
Masahiro Okamoto
Original Article Open access 06 September 2021 Pages: 156 - 163
Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients
Saki Kamiya
Hiroko Satake
Shinji Naganawa
Original Article 16 September 2021 Pages: 164 - 173
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Masato Takahashi
Eriko Tokunaga
Masakazu Toi
Original Article Open access 18 October 2021 Pages: 174 - 184
Correction to: Molecular targeted drugs resistance impairs double‑strand break repair and sensitizes ER‑positive breast cancer to PARP inhibitors
Yuna Suzuki
Wu Wenwen
Shin‑ichi Hayashi
Correction 22 August 2021 Pages: 185 - 185
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
Naruto Taira
Kosuke Kashiwabara
Fumikata Hara
Correction 25 September 2021 Pages: 186 - 188
Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study
Su-Jin Koh
Shozo Ohsumi
Judith Balmaña
Correction Open access 25 September 2021 Pages: 189 - 190
Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to “A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Japan”
Akihiko Ozaki
Kazunoshin Tachibana
Tohru Ohtake
Correction 13 October 2021 Pages: 191 - 191

Volume 29, Issue 1

Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan

Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?

Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging

Perceived physical fatigability improves after an exercise intervention among breast cancer survivors: a randomized clinical trial

Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer

Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of cN0 and cN + patients

LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299

Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer

Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy

Integrated analysis of cell cycle-related genes in HR+/HER2− breast cancer

Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

FE65 in breast cancer and its clinicopathological significance

Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Correction to: Molecular targeted drugs resistance impairs double‑strand break repair and sensitizes ER‑positive breast cancer to PARP inhibitors

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to “A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Japan”

Navigation